HER2阳性乳腺癌脑转移吡咯替尼联合颅脑放疗的时序:多中心真实世界队列
该回顾性两中心研究纳入101例接受颅脑放疗联合吡咯替尼的HER2阳性乳腺癌脑转移患者,按治疗时序分为同步组、吡咯替尼颅内进展后放疗组和放疗进展后吡咯替尼组。中位随访43.3个月,三组CNS-PFS与OS差异均无统计学意义;局灶性颅脑放疗与更长OS独立相关,毒性总体可控。
要点
- 治疗时序(同步、放疗后或吡咯替尼后放疗)未显著影响OS或CNS-PFS。
- 局灶性颅脑放疗与更长OS独立相关(HR 0.56,95%CI 0.34-0.94;P=0.028)。
- 总体毒性可控,≥3级不良事件各组均较低,放射性坏死7例(6.9%)。
核心结论
- 在HER2阳性乳腺癌脑转移患者中,颅脑放疗与吡咯替尼的治疗时序未显著影响OS或CNS-PFS。
- 局灶性颅脑放疗与更长OS独立相关,毒性可控。
研究设计与样本
- 回顾性、两中心真实世界队列研究,纳入101例接受颅脑放疗联合吡咯替尼的HER2阳性乳腺癌脑转移患者(2018年6月至2025年7月)。
- 按治疗时序分为同步放疗与吡咯替尼组(A组,n=41)、吡咯替尼颅内进展后放疗组(B组,n=38)、放疗进展后吡咯替尼组(C组,n=22);主要终点为CNS-PFS。
主要发现
- 中位随访43.3个月,63例(62.4%)死亡,70例(69.3%)发生CNS-PFS事件。
- 总体中位CNS-PFS为14.8个月(95%CI 10.68-19.92),A、B、C组分别为14.3、15.0、21.4个月(P=0.252)。
- 总体中位OS为36.0个月(95%CI 28.0-39.7),A、B、C组分别为33.0、35.4、42.0个月(P=0.281)。
- 局灶性颅脑放疗与更长OS独立相关(HR 0.56,95%CI 0.34-0.94;P=0.028)。
关键数值与推荐
- 任何级别不良事件发生于101例中的100例(99.0%)。
- ≥3级不良事件在A、B、C组分别为2.4%、7.9%、4.5%(均P>0.05)。
- 放射性坏死发生于7例(6.9%)。
- 探索性阈值:放疗早于吡咯替尼>3.9个月者OS 49.9个月对比29.8个月(HR 0.31,95%CI 0.11-0.91;P=0.025),但未通过内部验证。
临床怎么用
- 对于HER2阳性乳腺癌脑转移,颅脑放疗与吡咯替尼的先后顺序可依据临床情况个体化选择,不必强求某一固定时序。
- 在需要颅脑放疗时,局灶性放疗策略可能与更长生存相关,可结合病灶情况优先考虑。
- 放疗早于吡咯替尼>3.9个月的时序阈值仅为探索性假设,不宜直接用于临床决策。
局限性
- 回顾性真实世界研究,样本量较小(101例),存在选择偏倚可能。
- 探索性时序阈值未通过内部验证,需前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clin Transl Radiat Oncol . 2026 Oct 7;62:101310. doi: 10.1016/j.ctro.2026.101310. eCollection 2027 Jan. ABSTRACT BACKGROUND AND PURPOSE: Cranial radiotherapy (RT) and pyrotinib both demonstrate efficacy in HER2-positive breast cancer brain metastases (BCBM); however, the optimal sequencing of these modalities remains to be established. We evaluated survival across treatment sequences within a real-world cohort. MATERIALS AND METHODS: This retrospective, two-centre study included 101 patients with HER2-positive BCBM treated with cranial RT plus pyrotinib (June 2018-July 2025). Based on treatment sequence, patients were categorized into: concurrent RT and pyrotinib (Group A, n = 41); RT after intracranial progression on pyrotinib (Group B, n = 38); and pyrotinib upon progression following RT (Group C, n = 22). The primary endpoint was CNS-PFS. Survival outcomes were assessed via Kaplan-Meier estimation and Cox proportional hazards models. RESULTS: At a median follow-up of 43.3 months, 63 patients (62.4%) had died and 70 (69.3%) experienced CNS-PFS events. Median CNS-PFS was 14.8 months (95% CI 10.68-19.92) overall, and 14.3, 15.0, and 21.4 months in groups A, B, and C, respectively ( P = 0.252); median OS was 36.0 months (95% CI 28.0-39.7) overall, and 33.0, 35.4, and 42.0 months in groups A, B, and C, respectively ( P = 0.281). Focal cranial RT was independently associated with longer OS (HR 0.56, 95% CI 0.34-0.94; P = 0.028). Any-grade adverse events occurred in 100 of 101 patients (99.0%); grade ≥ 3 events occurred in 2.4%, 7.9%, and 4.5% of groups A, B, and C, respectively (all P > 0.05), and radiation necrosis occurred in 7 patients (6.9%). An exploratory threshold of RT initiated >3.9 months before pyrotinib (OS 49.9 vs 29.8 months; HR 0.31, 95% CI 0.11-0.91; P = 0.025) did not withstand internal validation. CONCLUSIONS: Treatment sequence did not significantly affect OS or CNS-PFS. Focal cranial RT was independently associated with longer survival, and toxicity was manageable. The proposed timing threshold is hypothesis-generating and warrants prospective validation. PMID: 42927325 | PMC: PMC13695302 | DOI: 10.1016/j.ctro.2026.101310
引用
- PubMed 顶刊 · 中枢神经:Timing of cranial radiotherapy in HER2-positive breast Cancer brain metastases treated with Pyrotinib: a multicentre real-world cohort study
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。